Gastroenterology

A history of bariatric surgery was associated with up to 50% reduced risk of PDAC among a national cohort.

How an outpatient-based smoking cessation model may come to aid other health systems' gastroenterology patients.

Investigators assess the detection rate of FIT and FIT-DNA among average-risk colorectal cancer screening individuals.

The Cleveland Clinic fellow explains why is upadacitinib is an essential tool in treating Crohn’s disease, especially in those who have previously failed conventional or biologic therapies.

In recent years trial designs have evolved to become increasingly complex and sophisticated with new endpoints that could include patient-reported outcomes, biomarkers, mucosal, and histological healing, central endoscopy reading, and trials that examine both induction and maintenance of remission within the same study.

BOS-580 is an investigational, proprietary, long-acting fibroblast growth factor 21 analog as a monthly and bi-weekly treatment for patients with NASH.

The treatment, developed by Intercept Pharmaceuticals, could not be approved in its present form, according to the CRL and any resubmission of the treatment for patients with NASH would require at least the successful completion of the long-term outcomes phase of the REGENERATE study.

NLR values were similar between significant and minimal fibrosis and were not correlated with significant fibrosis.

Patients with anti-HDV antibodies had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV co-infection compared to patients who demonstrated serum anti-HDV antibody negatively.

Men who have sex with men in Europe were more likely to be in a cluster compared to non-European men who have sex with men.

The race-neutral model resulted in worse calibration, NPV, and false-negative rates among racial and ethnic minority subgroups compared to non-Hispanic White participants.

There were no new safety signals identified from the COMMAND trial.

In the maintenance period, 86% of patients treated icanbelimod completed and 67% achieved clinical remission through week 48.

Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).

Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).

The point prevalence per 100,000 people at the conclusion of the study was 71.8 for autoimmune hepatitis, 38.5 for primary biliary cholangitis, and 11.0 for primary sclerosing cholangitis.

For individuals with hepatitis C virus infections, 52.5% of deaths were deemed attributable to the infection.

Patients with autoimmune hepatitis who were positive for antimitochondrial antibodies and evidence of non-specific bile duct injury had a higher risk of progressing to cirrhosis.

The possibility of clients reacting dismissively and of unsettling clients were viewed as the main barriers preventing better screening within these populations.

The treatment represents the first approval for pediatric patients with functional constipation.

After they adjusted for manufacturer rebates to estimate net prices, the investigators fund HCV drug prices decreased by 31% from 2013-2020.

David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).

Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.

David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

There were several risk factors identified, including abortion, hospitalization, past surgical procedure, dental extraction, delivery in hospital, injection in hospitals, and household contact with jaundice.

A beta diversity analyses revealed a distinct clustering pattern between healthy controls and patients with HBV-related liver disease and the composition of bacteria from the phylum level to the genus level varies across the stages of liver disease.